Gilles Favre, Director of CRCT

Gilles Favre is currently Professor of Biochemistry and Medical Biology at the University of Toulouse and director of the Clinical and Genetic Oncology Laboratory Medicine at the Institut Universitaire du Cancer de Toulouse-Oncopole for which he serves as the scientific director. He is also appointed as the director of the Cancéropole Grand Sud Ouest

His research focuses on cancer cell signalling leading to therapeutic targets identification and on translational medicine-based approaches to discover novel biomarkers.

He brought a major contribution to the cell biology of protein isoprenylation and strongly participated to the preclinical and clinical development of prenyltransferase inhibitors in cancer treatments. He contributed to elucidate the cell functions of RHOGTPases in genotoxic stress, DNA damage response and tumour progression. Recently, he developed new strategies to control RAS superfamily protein’s functions and to reverse resistance to targeted therapy in lung cancers and melanomas.

He is an active member of scientific societies including American Association for Cancer Research (AACR), and acquired a long experience in the evaluation of the research at the international level through his participation to International Scientific Advisory Board including Inserm, French National Cancer Institute (INCa), and Alberta Cancer Board (Edmonton, Canada).

Decision-making chart




The Scientific Advisory Board




Toulouse set up an original model of network for cancer care and research, referred to as GIP IUCT (Groupement d’Intérêt Public Institut Universitaire du Cancer de Toulouse). This network relies on a unique Scientific Advisory Board (SAB) consisting of 13 international experts – clinicians and researchers – to date. The global expertise of the SAB can be strengthened by the participation of other members with specific expertise. The main missions of the SAB are:

  • to give advice on scientific strategy for increasing the visibility and the attractiveness of the site,
  • to assess the medico-scientific programs,
  • to give independent opinion on the recruitment policy and projects submitted to annual Calls for proposals (launched by the IUCT, the IUCT-Oncopole and CRCT, and/or the Fondation Toulouse Cancer Santé).

More specifically, the SAB is in charge of giving advice on the scientific strategy, the recruitment policy and the current projects of the CRCT, as well as on the future five-year programme of the Center.


Members of the Scientific Advisory Board:


Madrid, Espagne

Centro Nacional de Investigaciones Oncologicas

GOUD Bruno

Paris, France

Institut Curie


Oxford, Royaume-Uni

Oxford Institute for Radiation Oncology


Bruxelles, Belgique

Ludwig Institute


Paris, France

Université Paris-Sud


Paris, France

IMI Coordinator


Paris, France

Institut Pasteur


Copenhague, Danemark

Rigshospitalet, Université de Copenhague


Barcelone, Espagne

Vall d’Hebron Institute of Oncology

EGLY Jean-Marc (prés.)

Strasbourg, France

Institut de Génétique et de Biologie Moléculaire et Cellulaire

KAY Cyril M.

Edmonton, Canada

Université d’Alberta


Villejuif, France

Institut Gustave Roussy